Physician profile
John M Joelson
NPI 1659355733
$3,634.35
in general payments reported to CMS, 2019-2025
21 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $265 · 2021: $509 · 2022: $618 · 2023: $584 · 2024: $695 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $503.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $482.84 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $466.70 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $448.06 | 2019-2022 | |
| Amgen INC. | $352.25 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $244.92 | 2019-2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.84 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $191.37 | 2021-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $131.48 | 2020-2023 | Onpattro |
| Cardiovascular Systems INC. | $116.40 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.81 | 2019-2024 | Lifevest |
| Novo Nordisk INC | $90.33 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Heartflow, INC. | $54.52 | 2023-2024 | Ffrct |
| Abbott Laboratories | $47.45 | 2019-2020 | |
| Bridgebio Pharma, INC. | $39.12 | 2025 | Attruby |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $29.32 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $27.61 | 2024 | |
| Sanofi-Aventis U.S. LLC | $23.85 | 2019 | |
| Amarin Pharma, INC. | $20.05 | 2021 | |
| Lundbeck LLC | $13.99 | 2019 | |
| Medtronic Vascular, INC. | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Joelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.